8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 27, 2026

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-36167		26-3931704
(State or Other Jurisdiction<br><br>of Incorporation)	(Commission<br><br>File Number)		(IRS Employer<br><br>Identification No.)
85 Wells Avenue, 2nd Floor<br><br>Newton, Massachusetts		02459
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617)

658-0600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading<br><br>Symbol(s)	Name of each exchange<br><br>on which registered
Common Stock, $0.0001 par value	KPTI	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01.	Entry into a Material Definitive Agreement.

On February 27, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into the Second Amendment to Credit and Guaranty Agreement (the “Amendment”) with the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent, which amends the Company’s Credit and Guaranty Agreement, dated May 8, 2024 (as previously amended, the “Credit Agreement”).

The purpose of the Amendment and the Forbearance Agreement (as defined below) is to reduce the capital required to extend the Company’s liquidity runway beyond the second quarter of 2026 and beyond the anticipated reporting of top-line data from the event driven, Phase 3 XPORT-EC 042 trial, which continues to be expected in mid-2026. The Amendment and Forbearance Agreement permit the Company to defer certain principal and interest payments until September 2026, maintain the Company’s existing minimum liquidity covenant of $10.0 million through October 10, 2026, and eliminate the requirement that 50% of proceeds from financing activities be applied to increase the minimum liquidity covenant; provided, in each case, that the Capital Raise Trigger (as defined below) is met.

Amendment to the Credit Agreement

The Amendment provides that, if the Company consummates a sale and issuance of the Company’s common stock, in one or more transactions, resulting in proceeds to the Company of not less than $25.0 million actually received in cash before June 10, 2026 (the “Capital Raise Trigger”), (i) the Company’s cash interest payment otherwise payable on June 30, 2026 will be paid in kind on June 30, 2026 and (ii) the principal installment otherwise due on June 10, 2026 will instead be due on September 10, 2026. The Amendment also amends the Credit Agreement’s minimum consolidated liquidity covenant. Under the existing covenant, the Company must maintain minimum liquidity of at least the lesser of (a) $25.0 million and (b) $10.0 million plus 50% of the net cash proceeds received from certain debt and equity issuances through October 10, 2026. The Amendment provides that proceeds received in connection with a capital raise that satisfies the Capital Raise Trigger will be excluded from this calculation, so that such proceeds do not cause the minimum liquidity requirement to increase. After October 10, 2026, the covenant continues to require minimum consolidated liquidity of $25.0 million.

The Amendment also modifies the prepayment premium provided in the Credit Agreement such that (i) application of a 5% prepayment premium would extend through and including June 10, 2026 and (ii) if the Capital Raise Trigger occurs, such application of a 5% prepayment premium would be extended through May 8, 2027 (and 0% thereafter).

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 8.01.	Other Items.

Forbearance Agreement

On February 27, 2026, the Company entered into a Forbearance Agreement (the “Forbearance Agreement”) with (i) 100% of the lenders under the Credit Agreement, (ii) holders representing 100% of the outstanding principal amount of the Company’s 9.00% Convertible Senior Notes due 2028 (the “2028 Notes”), (iii) holders representing 100% of the outstanding principal amount of the Company’s 9.00% Convertible Senior Notes due 2029 (the “2029 Notes”), and (iv) the investor representative acting at the direction of the investors under the Company’s revenue interest financing agreement (collectively, the “Consenting Parties”).

The effectiveness of the Forbearance Agreement is conditioned on, among other things, the occurrence of the Capital Raise Trigger. Upon effectiveness, the Consenting Parties agreed to forbear from exercising certain rights and remedies with respect to specified matters, including (i) payment-related defaults that would result from the Company’s non-payment of the cash interest payments due June 30, 2026 under the indentures governing the 2028 Notes and 2029 Notes (and related cross-defaults) and (ii) any minimum liquidity-related defaults that would result from the minimum liquidity covenants under such indentures to the extent impacted by an increase in the applicable liquidity threshold resulting from such equity financing (and related cross-defaults).

Under the Forbearance Agreement, the forbearance with respect to the specified payment matters would continue until September 30, 2026, and the forbearance with respect to the specified minimum liquidity matters would continue until October 10, 2026, in each case unless terminated earlier upon the occurrence of certain customary termination events. The

Forbearance Agreement does not constitute a waiver of any defaults or events of default, and the Consenting Parties reserve their rights and remedies, subject to the terms of the Forbearance Agreement.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the Company’s expected cash runway and liquidity and whether the Capital Raise Trigger will occur. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond the Company’s control, that may cause actual events or results to differ materially from the Company’s current expectations. For example, there can be no guarantee that the Company will successfully commercialize XPOVIO or that any of the Company’s drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of the Company’s drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of the Company’s drug candidate portfolio will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this Current Report on Form 8-K could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of the Company’s drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of the Company’s drug candidates that receive regulatory approval; the Company’s results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical trials; the ability of the Company’s or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; the Company’s ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; substantial doubt exists regarding the Company’s ability to continue as a going concern; development or regulatory approval of drug candidates by the Company’s competitors for products or product candidates in which Karyopharm is currently commercializing or developing; and the Company’s ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (SEC) on February 13, 2026, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01	Financial Statements and Exhibits.

(d) Exhibits

Exhibit<br><br>No.	Description
10.1	Second Amendment to Credit and Guaranty Agreement, dated February 27, 2026
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KARYOPHARM THERAPEUTICS INC.
Date: March 2, 2026	By:	/s/ Michael Mano
		Michael Mano
		Executive Vice President, Chief Legal Officer and Secretary

EX-10.1

Exhibit 10.1

Execution Version

SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT

SECOND AMENDMENT TO CREDIT AND GUARANTY AGREEMENT, dated as of February 27, 2026 (this “Amendment”), made by and among Karyopharm Therapeutics Inc., a Delaware corporation (“Company”) as borrower, the Lenders party hereto from time to time, and Wilmington Savings Fund Society, FSB (“WSFS”), as administrative agent for the Lenders (in such capacity, “Administrative Agent”) and collateral agent for the Secured Parties (in such capacity, “Collateral Agent”).

RECITALS:

WHEREAS, reference is hereby made to the Credit and Guaranty Agreement, dated as of May 8, 2024, as amended by that certain First Amendment and Waiver to Credit and Guaranty Agreement, dated as of October 7, 2025 (as further amended, restated, amended and restated, supplemented or otherwise modified from time to time and immediately prior to the Second Amendment Effective Date, the “Existing Credit Agreement”), by and among the Company, as borrower and certain of its Subsidiaries from time to time party thereto as Guarantors, the Administrative Agent, each Lender from time to time party thereto, the Collateral Agent and the other parties party thereto (capitalized terms used but not defined herein having the meaning provided in the Amended Credit Agreement (as defined below));

WHEREAS, the Company has requested that, pursuant to Section 10.5(b) of the Existing Credit Agreement, and the Administrative Agent and each Lender party hereto (constituting all Lenders as of the date hereof under the Existing Credit Agreement) has agreed, to effect the amendments set forth herein, and agree to the terms of this Amendment and the Amended Credit Agreement, on the terms and subject to the conditions set forth in this Amendment;

WHEREAS, the Company and each other Credit Party expects to realize substantial direct and indirect benefits as a result of this Amendment becoming effective and the consummation of the transactions contemplated hereby and thereby and agrees to reaffirm its obligations pursuant to the Collateral Documents, and the other Credit Documents to which it is a party.

NOW, THEREFORE, in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto agree as follows:

• Amendments to the Agreement. Effective as of the Second Amendment Effective Date:
• The definition of “Credit Document” shall be amended to add “, the Second Amendment, the 2026 Forbearance Agreement” immediately following “First Amendment Fee Letter”.
• The following defined terms shall be added to Section 1.1 of the Existing Credit Agreement, in their proper alphabetical order:

“2026 Forbearance Agreement” means that certain Forbearance Agreement, dated as of February 27, 2026, made by and among the Company and the other parties thereto.

“Capital Raise Trigger” means the consummation of a sale and issuance by the Company of Common Stock (including the issuance of any warrants exercised (or, in the case of pre-funded warrants, exercisable) directly into Common Stock) occurring at any time after February 27, 2026 that results in unrestricted (including, not subject to any redemption, clawback, escrow or similar encumbrance or restriction) gross proceeds actually received in cash by the Company of not less than $25,000,000, in one

or more transactions, before June 10, 2026. The Company shall notify the Administrative Agent promptly, and in any event no later than one (1) Business Day after the occurrence of the Capital Raise Trigger.

“Second Amendment” means that certain Second Amendment to Credit and Guaranty Agreement, dated as of February 27, 2026, made by and among the Company, the Lenders party thereto, the Administrative Agent and the Collateral Agent.

• The definition of Prepayment Premium in Section 1.1 of the Existing Credit Agreement is hereby amended and restated as follows:

“Prepayment Premium” means the amount set forth in the chart below, determined by reference to the date of prepayment:

• To the extent the Capital Raise trigger has not occurred:

Date of Prepayment	Prepayment Premium
Closing Date through and including May 8, 2025	Make-Whole Premium
May 9, 2025 though and including June 10, 2026	5.00% of the aggregate principal amount of the Term Loan subject to such prepayment
June 11, 2026 through and including May 8, 2027	3.00% of the aggregate principal amount of the Term Loan subject to such prepayment
May 9, 2027 and thereafter	0.00% of the aggregate principal amount of the Term Loan subject to such prepayment

• To the extent the Capital Raise Trigger has occurred:

Date of Prepayment	Prepayment Premium
Closing Date through and including May 8, 2025	Make-Whole Premium
May 9, 2025 through and including May 8, 2027	5.00% of the aggregate principal amount of the Term Loan subject to such prepayment
May 9, 2027 and thereafter	0.00% of the aggregate principal amount of the Term Loan subject to such prepayment

• Section 2.7(e) of the Existing Credit Agreement is hereby amended and restated as follows:

Except as otherwise set forth herein, interest on each Loan (i) shall accrue on a daily basis and shall be payable in arrears, in Cash, on each Interest Payment Date with respect to interest accrued on and to each such Interest Payment Date; (ii) shall accrue on a daily basis and shall be payable in arrears upon any prepayment of that Loan, whether voluntary or mandatory, to the extent accrued on the amount being prepaid; and (iii) shall accrue on a daily basis and shall be payable in arrears at maturity of the Loans, including final maturity of the Loans, provided, that (x) the interest on the Loans that was due on September 30, 2025 shall be paid in kind by being capitalized, added to, and made part of, the outstanding principal

-2-

amount of the Loans on the First Amendment Effective Date (for the avoidance of doubt, at the Applicable Margin for such Interest Payment Date after giving effect to the First Amendment), (y) from and after the First Amendment Effective Date, for any Interest Payment Date or portion of any Interest Period on or prior to March 31, 2026, interest on the Loans, shall be payable in kind which such in-kind interest shall be capitalized, added to, and made part of, the outstanding principal amount of the Loans on the applicable Interest Payment Date and payable as part of the outstanding principal amounts of the Loans upon any prepayment of the Loans, whether voluntary or mandatory, and shall be payable as part of the outstanding principal amount of Loans upon the Maturity Date and (z) solely to the extent the Capital Raise Trigger has occurred, the Interest Payment due on June 30, 2026, shall be paid in kind by being capitalized, added to, and made part of, the outstanding principal amount of the Loans on June 30, 2026 and payable upon any prepayment of the Loans, whether voluntary or mandatory, and shall be payable as part of the outstanding principal amount of Loans upon the Maturity Date.

• Section 2.11 of the Existing Credit Agreement is hereby amended and restated as follows:

Scheduled Payments. The principal amounts of the Term Loans shall be repaid in consecutive quarterly installments (each such payment, an “Installment”) on the tenth day of each March, June, September and December commencing on June 10, 2026 (each such date, an “Installment Payment Date”), in an amount equal to the product of (x) 6.25% multiplied by (y) the aggregate original stated principal amount of all Term Loans made under this Agreement prior to such Installment Payment Date (without reducing any such Installment to reflect payments of the outstanding principal of any Term Loan after the initial funding thereof); provided that, notwithstanding the foregoing, solely to the extent the Capital Raise Trigger has occurred, no Installment shall be due on June 10, 2026 and the Installment due on September 10, 2026 shall be increased by the amount that would have been due on June 10, 2026 but for the occurrence of the Capital Raise Trigger. Notwithstanding the foregoing, the Term Loans, together with all other amounts owed hereunder with respect thereto, shall, in any event, be Paid in Full on the Maturity Date.

• Section 6.8 of the Existing Credit Agreement is hereby amended and restated as follows:

Minimum Consolidated Liquidity. The Company shall not permit Consolidated Liquidity at any time to be (i) for the period commencing on the Closing Date, to but excluding the First Amendment Effective Date, less than $25,000,000, (ii) for the period commencing on the First Amendment Effective Date through and including October 10, 2026, less than the lesser of (A) sum of (x) $10,000,000 and (y) 50% of the net cash proceeds of any issuance of Indebtedness for borrowed money or Capital Stock of the Company or any of its Subsidiaries (but not including the issuance of Indebtedness or Capital Stock to the Company or any of its Subsidiaries) occurring after the First Amendment Effective Date and prior to October 10, 2026 (not including (x) for the avoidance of doubt, any net cash proceeds of any First Amendment Transaction and (y) any net cash proceeds in connection with a Capital Raise Trigger) and (B) $25,000,000 and (iii) at any time after October 10, 2026, less than $25,000,000.

• Section 10.2 of the Existing Credit Agreement is hereby amended by adding “(including any financial or investment advisors)” immediately following “advisors” in clause (f) thereof.
• Conditions to Second Amendment Effective Date. The effectiveness of the amendments set forth in Section 1 are subject to the satisfaction (or wavier by each Lender, the Administrative Agent and the Collateral Agent, each in its respective sole discretion) of the following conditions (such date, the “Second Amendment Effective Date”).

-3-

• this Amendment shall have been executed and delivered by Company, the Administrative Agent, the Collateral Agent and each Lender;
• the Administrative Agent and the Lenders shall have received a duly executed counterpart of the 2026 Forbearance Agreement; and
• the Administrative Agent, the Collateral Agent and the Lenders shall have received in full in cash on or before the Second Amendment Effective Date, all fees and reasonable and documented out-of-pocket expenses incurred in connection with the negotiation, preparation and execution of this Amendment (including, without limitation, the reasonable and documented fees, out of pocket expenses and disbursements of legal counsel to the Agents, and each legal counsel to Lenders and, if reasonably necessary, of one local counsel to the Agents and of one local counsel to the Lenders (which may include a single special counsel acting in multiple jurisdictions) in each case, in each relevant jurisdiction material to the interests of the Agents and the Lenders) that are invoiced at least one (1) Business Day prior to the Second Amendment Effective Date (or such later time as the Company may agree).
• Representations and Warranties. The Company represents and warrants to the Administrative Agent, the Collateral Agent and the Lenders on the Second Amendment Effective Date that:
• It has all requisite power and authority to enter into this Amendment and to carry out the transactions contemplated hereunder. The execution, delivery and performance of this Amendment has been duly authorized by all necessary action on the part of the Company.
• The execution, delivery and performance by the Company of this Amendment, and the consummation of the transactions contemplated hereby do not and will not, as of the Second Amendment Effective Date, (i) violate any provision of any material Requirement of Law applicable to it or any of its Subsidiaries, any of the Organizational Documents of it or any of its Subsidiaries, or any order, judgment or decree of any court or other agency of government binding on it or any of its Subsidiaries; (ii) conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default or give rise to any right of termination, amendment cancellation or acceleration of any obligation or the loss of any material benefit or the triggering of any payment under any Credit Document, any Material Contract or any Related Agreement; (iii) result in or require the creation or imposition of any Lien upon any of the properties or assets of it or any of its Subsidiaries (other than any Liens created under any of the Credit Documents in favor of the Collateral Agent, for the benefit of Secured Parties); or (iv) require any approval of stockholders, members or partners or any approval or consent of any Person under any Material Contract or any Related Agreement except for such approvals or consents that have been obtained on or before the Second Amendment Effective Date.
• No event (other than the Term Loan Specified Matters (as defined in the 2026 Forbearance Agreement)) shall have occurred and be continuing or would result from the consummation of the transactions contemplated hereunder that would constitute an Event of Default or a Default.
• Since the Closing Date, no fact, circumstance, occurrence, change or event has occurred that constitutes, or would reasonably be expected to individually or in the aggregate, in material adverse change in, or a material adverse effect on, the operations, business, properties or financial condition so the Credit Parties, taken as a whole.
• As of the Second Amendment Effective Date, each of the representations and warranties of the Company and the Guarantors, set forth in this Amendment, the Amended Credit Agreement and in the other Credit Documents shall be true and correct in all material respects (except for

-4-

• those which have a materiality qualifier, which shall be true and correct in all respects as so qualified), except to the extent any such representations and warranties are expressly limited to an earlier date, in which case, such representations and warranties shall be true and correct in all material respects (except for those which have a materiality qualifier, which shall be true and correct in all respects as so qualified) as of such specified earlier date.
• Reaffirmation. Each Credit Party, hereby consents to the amendment of the Existing Credit Agreement effected hereby and the transactions contemplated hereby and confirms and agrees that, notwithstanding the effectiveness of this Amendment, each Credit Document to which Company and the other Credit Parties are a party and the obligations of the Credit Parties contained in the Amended Credit Agreement, this Amendment or in any other Credit Document to which they are a party are, and shall continue to be, in full force and effect and are hereby ratified and confirmed in all respects, in each case as amended by this Amendment. For greater certainty and without limiting the foregoing, each Credit Party hereby (i) confirms the obligations of such Credit Party under the Amended Credit Agreement and the other Credit Documents are entitled to the benefits of the guarantees and the security interests set forth or created in the Collateral Documents and the other Credit Documents and constitute Obligations and (ii) confirms the existing security interests granted in favor of the Collateral Agent for the benefit of, among others, the Lenders pursuant to the Credit Documents in the Collateral described therein, which security interests shall continue in full force and effect after giving effect to this Amendment and any transaction contemplated hereby to secure the obligations of the Credit Parties under the Amended Credit Agreement and the other Credit Documents as and to the extent provided in the Credit Documents.
• Entire Agreement. This Amendment, the other Credit Documents and any separate letter agreements with respect to fees payable comprises the complete and integrated agreement of the parties on the subject matter hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter. On and after the Second Amendment Effective Date, each reference in the Amended Credit Agreement to “this Amendment,” “hereunder,” “hereof” or words of like import referring the Amended Credit Agreement, and each reference in the other Credit Documents to “the Credit Agreement,” “thereunder,” “thereof” or words of like import referring to the Amended Credit Agreement, shall mean and be a reference to the Existing Credit Agreement, as amended by this Amendment.
• Governing Law and Waiver of Right to Trial by Jury.
• THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER (INCLUDING ANY CLAIMS SOUNDING IN CONTRACT LAW OR TORT LAW ARISING OUT OF THE SUBJECT MATTER HEREOF AND ANY DETERMINATIONS WITH RESPECT TO POST-JUDGMENT INTEREST) SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAW OF THE STATE OF NEW YORK.
• The consent to jurisdiction and waiver of right to trial by jury provisions in Sections 10.15 and 10.16 of the Amended Credit Agreement are incorporated herein by reference mutatis mutandis.
• Severability. In the event any provision in or obligation hereunder shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby (it being understood that the invalidity, illegality or unenforceability of a particular provision in a particular jurisdiction shall not in and of itself affect the validity, legality or

-5-

• enforceability of such provision in any other jurisdiction). The parties hereto shall endeavor in good faith negotiations to replace any invalid, illegal or unenforceable provisions with valid, legal and enforceable provisions the economic effect of which comes as close as reasonably possible to that of the invalid, illegal or unenforceable provisions.
• Counterparts. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Amendment. The Administrative Agent may also require that any such documents and signatures delivered by telecopier be confirmed by a manually signed original thereof; provided that the failure to request or deliver the same shall not limit the effectiveness of any document or signature delivered by telecopier. The words “execution,” “execute”, “signed,” “signature,” “delivery,” and words of like import in or relating to this Amendment or any document to be signed in connection with this Amendment or the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
• No Novation. This Amendment is not intended to constitute and shall not constitute a novation of the Existing Credit Agreement or any of the Credit Documents.
• Agent. Notwithstanding anything in this Agreement or in any other Credit Document to the contrary, each Agent shall be entitled to all of the rights, powers, privileges, immunities, benefits, protections, indemnities and remedies afforded to such Agent as expressly provided for in the Amended Credit Agreement, and the other Credit Documents to which it is a party. This Section 11 shall survive the resignation or replacement of any Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and Payment in Full of the Obligations.
• Acknowledgement and Instructions. Each Lender, by delivering its signature page to this Amendment shall be deemed to have (i) acknowledged receipt of, and consented to and approved this Amendment and each other Credit Document, and each other document required to be approved by the Lenders on the Second Amendment Effective Date and (ii) instructed each Agent to enter into this Amendment and each other Credit Document to which it is party.

[signature pages to follow]

-6-

IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to execute and deliver this Amendment as of the date first set forth above.

COMPANY:

KARYOPHARM THERAPEUTICS INC.

By:	/s/ Richard Paulson
	Name: Richard Paulson
	Title: President and Chief Executive Officer

[Signature Page to Amendment No. 2]

ADMINISTRATIVE AGENT:

WILMINGTON SAVINGS FUND SOCIETY, FSB

By:	/s/ Raye Goldsborough
	Name: Raye Goldsborough
	Title: Vice President

COLLATERAL AGENT:

WILMINGTON SAVINGS FUND SOCIETY, FSB

By:	/s/ Raye Goldsborough
	Name: Raye Goldsborough
	Title: Vice President

[Signature Page to Amendment No. 2]

LENDERS:

1992 Master Fund Co-Invest SPC - Series 4 Segregated Portfolio, as a Lender

By: Highbridge Capital Management, LLC,

as Trading Manager and not in its individual capacity

By:	/s/ Christopher Casale
	Name: Christopher Casale
	Title: Authorized Signatory

HIGHBRIDGE TACTICAL CREDIT INSTITUTIONAL FUND, LTD., as a Lender

By: Highbridge Capital Management, LLC,

as Trading Manager and not in its individual capacity

By:	/s/ Christopher Casale
	Name: Christopher Casale
	Title: Authorized Signatory

HIGHBRIDGE TACTICAL CREDIT MASTER FUND, L.P., as a Lender

By: Highbridge Capital Management, LLC,

as Trading Manager and not in its individual capacity

By:	/s/ Christopher Casale
	Name: Christopher Casale
	Title: Authorized Signatory

Highbridge SCF II Loan SPV, L.P., as a Lender

By: Highbridge Capital Management, LLC,

as Trading Manager and not in its individual capacity

By:	/s/ Christopher Casale
	Name: Christopher Casale
	Title: Authorized Signatory

[Signature Page to Amendment No. 2]

BRAIDWELL TRANSACTION HOLDINGS LLC – SERIES 7, as a Lender

By: Braidwell LP, its Investment Manager

By:	/s/ Colin Bettison
	Name: Colin Bettison
	Title: Head of Finance & Operations

[Signature Page to Amendment No. 2]

Context Partners Master Fund, L.P., as a Lender

By: Context Capital Management, LLC,

Investment Adviser

By:	/s/ Charles Carnegie
	Name: Charles Carnegie
	Title: Managing Member<br><br>Context Capital Management, LLC<br><br>Investment Advisor

[Signature Page to Amendment No. 2]

Midtown Acquisitions, L.P., as a Lender

By: Midtown Acquisitions GP LLC, its general partner

By:	/s/ Gabriel T. Schwartz
	Name: Gabriel T. Schwartz
	Title: Managing Member

[Signature Page to Amendment No. 2]

GARX I, L.P., as a Lender

By:	/s/ Clarke B. Futch
	Name: Clarke B. Futch
	Title: Managing Partner

HEALTHCARE ROYALTY PARTNERS IV, L.P., as a Lender

By: HealthCare Royalty GP IV, LLC, its general partner

By:	/s/ Clarke B. Futch
	Name: Clarke B. Futch
	Title: Managing Partner

HCRX INVESTMENT HOLDCO, L.P., as a Lender

By: HCRX Master GP, LLC, its general partner

By:	/s/ Clarke B. Futch
	Name: Clarke B. Futch
	Title: Managing Partner

HCR CANARY FUND, L.P., as a Lender

By: HCR Canary Fund GP, LLC, its general partner

By:	/s/ Clarke B. Futch
	Name: Clarke B. Futch
	Title: Managing Partner

HCR MOLAG FUND, L.P.

By: HCR Molag Fund GP, LLC, its general partner

By:	/s/ Clarke B. Futch
	Name: Clarke B. Futch
	Title: Managing Partner

[Signature Page to Amendment No. 2]